SlideShare a Scribd company logo
La TB nelle aree metropolitane




L.R. Codecasa, M. Ferrarese
Centro Regionale di Riferimento per il controllo della
TBC
Istituto Villa Marelli. AO Niguarda, Milano
The winter of our discontempt….
(W. Shakespeare, Richard III)
TBC nelle grandi città europee
                      50
Casi	
  x	
  100000




                      45
                      40
                      35
                      30
                      25
                      20
                      15
                      10
                       5
                       0
                           Londra   Milano   Rotterdam   Barcellona   Parigi
Trend incidenza TBC e media 2000 - 2010
                        25                           Milano        Lombardia         Italia
Casi	
  x	
  100.000




                        20                                                                               19,1

                        15


                        10                                                                               10,1

                         5                                                                          7,5

                         0
                             2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
                       Incidenza nazionale stabile ma con:
                       •  Differenze territoriali rilevanti
                       •  Valori significativamente più elevati nelle aree metropolitane (ASL Milano, notifica il
                       40% dei casi regionali e il 9% dei casi nazionali di TBC)
Numero	
  casi	
  TBC	
  per	
  fascia	
  d’età	
  e	
  nazionalità	
  -­‐	
  2010	
  
                                     	
  




 Negli	
  italiani	
  la	
  TBC	
  colpisce	
  sopra2u2o	
  gli	
  anziani,	
  negli	
  stranieri	
  l’età	
  
 giovane	
  –	
  adulta	
  con	
  picco	
  nella	
  fascia	
  30	
  –	
  39	
  anni	
  	
  	
  
TBC	
  in	
  stranieri	
  	
  


                      Area di
                    provenienza




                                        15%

 Casi TBC dal Sud                             27%
     America
- Quota ++ in
  rapporto ai residenti -
- Quota femmine +                       25%
   dei maschi


                                  31%



     maschi	
     femmine	
  
RischioTBC	
  in	
  stranieri:	
  10	
  nazionalità	
  più	
  frequen@	
  a	
  confronto	
  con	
  
le	
  presenze	
  sul	
  territorio	
  




      * Paesi di origine ad elevata incidenza TBC (≥ 100 casi x
"   Il numero dei casi anno è il 5%
     dei casi totali segnalati
"   In media ogni mese viene segnalato 1 caso che
    frequenta collettività scolastiche
"   La proporzione di bambini stranieri è simile a
    quella dei casi adulti
L’andamento della TBC nei bambini non preoccupa, ma esistono nella
popolazione i fattori di rischio per lo sviluppo di micro-epidemie nelle
comunità infantili
POLMONITE	
  BILATERALE?	
  
" Perù,	
  13	
  anni	
  
" Calo	
  ponderale	
  15	
  kg,	
  
  febbre,	
  tosse.	
  
" RichiesO	
  anOcorpi	
  
  anOgliadina!	
  
" QuanOferon	
  +	
  
" Inviata	
  per	
  profilassi	
  
  con	
  isoniazide	
  
" Esame	
  dire2o	
  posiOvo	
  
  per	
  BAAR+++	
  
..e	
  il	
  fratellino!
                       	
  
Le Regioni che hanno attivato la sorveglianza ed hanno inviato informazioni sugli esiti sono state Emilia-Romagna, Friuli Venezia
 Giulia, Lombardia, Marche, Piemonte, Toscana e Veneto, Regioni che rappresentavano il 71% dei casi di TBC notificati a livello
 nazionale nel 2007



                                                                                                      Sono pervenute
                                                                                                      informazioni sugli esiti
                                                                                                      di 1.818 casi di TBC
                                                                                                      polmonare su 2.107.




                                                                                                   Esiti di trattamento TBC
                                                                                                  per pervenuti per Regione
                                                                                                           Anno 2007




                                                                                                                D.G. Prevenzione Sanitaria
                                                                                                                Ufficio Malattie Infettive e
Fonte: La tubercolosi in Italia. Rapporto 2008 – www.salute.gov.it                                               Profilassi Internazionale
Esi@	
  della	
  terapia	
  casi	
  di	
  TBC	
  2009	
  
 Non	
  pervenuto   Sfavorevole     Favorevole
                                                      Cause	
  esito	
  
                                                      sfavorevole	
  
                        7,4                           Perso	
  al	
  follow	
  	
  up	
  
                                                      (43%)	
  
                                  19,3                	
  
                                                      Trasferito	
  17	
  %	
  
                                                      Decesso	
  17	
  %	
  
                                                      Interro2o	
  15%	
  

                73,3                                  Fallimento/altro	
  8%	
  




          Obiettivo OMS: trattare con successo 85% dei casi
  Differenze significative degli esiti della terapia tra centri ospedalieri:
         Villa Marelli tratta con successo oltre il 90% dei malati
There is an increased drive to use awareness as a measure for TB control and to
improve the lack of knowledge, also in EU countries [55]. Mass TB awareness
campaigns in general population may not be effective [56], but early suspicion is
more likely when knowledge about TB among is increased in the exposed
population, high-risk groups, staff working with high-risk groups and health care
professionals
Infection control in community settings and big cities

Infection control (IC) is an essential component of TB control and prevention, including
WHO´s updated Stop TB strategy and the EU Standards of TB Care [65-73].
Shortcomings in IC were major contributors to nosocomial outbreaks [74-76], even in
European TB reference. Poor ventilation and overcrowding have been drivers of TB
transmission in congregate settings such as homeless shelters, prisons and drug
consumption houses [78-80]. General IC principles for health care settings, described
in detail elsewhere [74, 81], can benefit these specific congregate venues. However,
engeneering control activities may be difficult to implement in existing buildings and
other measures, such as personal protective equipment for employees, cannot be
expected. New interest in IC has been awakened by the emergence of multi-drug
resistant (MDR) and extensively-drug resistant (XDR) TB
Active case finding among urban high-risk groups should be complemented by tailored
opportunities for completion of the diagnostic process and treatment, e.g. through low-
threshold public health "One-Stop-TB-Shops" with sufficient nursing, social and community
health care worker staff, clinical follow-up or admission to general hospitals or modern-day
sanatoria, adequate legal frameworks for social support and protection and ensuring
knowledge about and facilitating access to health care services. Contact-tracing may not be
feasible or effective amongst all urban risk groups, but can be in specific populations, e.g.
household or professional contacts [4, 12]. Indiscriminate radiographic screening of
immigrants is described as inefficient and not cost-effective [9, 69, 98, 101, 103]. However,
some interventions may be highly effective or cost-effective when targeted at specific urban
high-risk groups, e.g. homeless persons and prisoners
The contribution of DNA fingerprinting to the epidemiological standard data in the
context of urban TB control have been described elsewhere, with an extensive list of
references [142]. Briefly, molecular indications for epidemiological links and
identification of risk factors for transmission are crucial for understanding the specific
epidemiology of TB in big cities, allowing the detection of risk groups and informing
(targeted) public health interventions [12, 19]. Since the 1990's DNA fingerprinting
revealed that a considerable proportion of TB in low-incidence countries was caused
by recent transmission (including reinfection), in particular in urban areas, and not
due to late reactivation of infections acquired domestically or infections acquired
abroad. Molecular epidemiological studies identified factors for a higher risk of
clustering, reflecting the risk of infection, such as alcohol abuse, intravenous drug use
(IDU), homelessness, or ethniticy [142]. They also confirmed high-risk sites for TB
transmission in big cities, e.g. congregate settings such as shelters for homeless
persons or prisons. Not sure this is the best way to phrase this but I was trying to put
here what is in the reco : that molecular tools complement the surveillance data
Sostenete	
  Stop	
  TB	
  Italia!
                                 	
  
     www.stoptb.it         	
  

More Related Content

Similar to PPT Codecasa "Urban TB control"

TB DAY 2022 - Ritorno al futuro
TB DAY 2022 - Ritorno al futuroTB DAY 2022 - Ritorno al futuro
TB DAY 2022 - Ritorno al futuro
Stop TB Italia Onlus
 
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
StopTb Italia
 
Counting children with TB - the role of modelling
Counting children with TB - the role of modellingCounting children with TB - the role of modelling
Counting children with TB - the role of modelling
cheweb1
 
Epidemiological indices afk
Epidemiological indices   afkEpidemiological indices   afk
Epidemiological indices afk
FarisAhamed2
 
Journal.pmed.1002152
Journal.pmed.1002152Journal.pmed.1002152
Journal.pmed.1002152
Julio A. Diaz M.
 
6249919.ppt
6249919.ppt6249919.ppt
6249919.ppt
Esam43
 
TB PPT 2022.pptx
TB PPT 2022.pptxTB PPT 2022.pptx
TB PPT 2022.pptx
MohammedAbdela7
 
"What Will It Take To Control TB?" Richard Chaisson, MD
"What Will It Take To Control TB?" Richard Chaisson, MD"What Will It Take To Control TB?" Richard Chaisson, MD
"What Will It Take To Control TB?" Richard Chaisson, MD
UWGlobalHealth
 
TB Working Group_Kayt E_10.13.11
TB Working Group_Kayt E_10.13.11TB Working Group_Kayt E_10.13.11
TB Working Group_Kayt E_10.13.11
CORE Group
 
Drug resistant TB – latest developments in epidemiology, diagnostics and mana...
Drug resistant TB – latest developments in epidemiology, diagnostics and mana...Drug resistant TB – latest developments in epidemiology, diagnostics and mana...
Drug resistant TB – latest developments in epidemiology, diagnostics and mana...
VictorAkinseyeOluwat
 
Presentation1-2.pptx
Presentation1-2.pptxPresentation1-2.pptx
Presentation1-2.pptx
BarnabasKipngetich
 
Dec2010 1final ll
Dec2010 1final llDec2010 1final ll
Dec2010 1final ll
Lut Lynen
 
The eleven lectures of the Tuberculosis.ppt
The eleven lectures of the Tuberculosis.pptThe eleven lectures of the Tuberculosis.ppt
The eleven lectures of the Tuberculosis.ppt
ibrahimabdi22
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
Jehad Alqurashi
 
Training on tuberculosis for counselors 2012
Training on tuberculosis for counselors 2012Training on tuberculosis for counselors 2012
Training on tuberculosis for counselors 2012
Madhu Oswal
 
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
European Centre for Disease Prevention and Control
 
Dengue
DengueDengue
Influence of population density and access to sanitation on covid 19 in mozam...
Influence of population density and access to sanitation on covid 19 in mozam...Influence of population density and access to sanitation on covid 19 in mozam...
Influence of population density and access to sanitation on covid 19 in mozam...
Revista Angolana de Ciências da Saúde
 
Infectious Disease
Infectious DiseaseInfectious Disease
Infectious Disease
Deep Deep
 
TOPIC - ABDIKADIR ISSE ABDI (2020-01-01111).pptx
TOPIC - ABDIKADIR ISSE ABDI (2020-01-01111).pptxTOPIC - ABDIKADIR ISSE ABDI (2020-01-01111).pptx
TOPIC - ABDIKADIR ISSE ABDI (2020-01-01111).pptx
fatumaabdinour
 

Similar to PPT Codecasa "Urban TB control" (20)

TB DAY 2022 - Ritorno al futuro
TB DAY 2022 - Ritorno al futuroTB DAY 2022 - Ritorno al futuro
TB DAY 2022 - Ritorno al futuro
 
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
 
Counting children with TB - the role of modelling
Counting children with TB - the role of modellingCounting children with TB - the role of modelling
Counting children with TB - the role of modelling
 
Epidemiological indices afk
Epidemiological indices   afkEpidemiological indices   afk
Epidemiological indices afk
 
Journal.pmed.1002152
Journal.pmed.1002152Journal.pmed.1002152
Journal.pmed.1002152
 
6249919.ppt
6249919.ppt6249919.ppt
6249919.ppt
 
TB PPT 2022.pptx
TB PPT 2022.pptxTB PPT 2022.pptx
TB PPT 2022.pptx
 
"What Will It Take To Control TB?" Richard Chaisson, MD
"What Will It Take To Control TB?" Richard Chaisson, MD"What Will It Take To Control TB?" Richard Chaisson, MD
"What Will It Take To Control TB?" Richard Chaisson, MD
 
TB Working Group_Kayt E_10.13.11
TB Working Group_Kayt E_10.13.11TB Working Group_Kayt E_10.13.11
TB Working Group_Kayt E_10.13.11
 
Drug resistant TB – latest developments in epidemiology, diagnostics and mana...
Drug resistant TB – latest developments in epidemiology, diagnostics and mana...Drug resistant TB – latest developments in epidemiology, diagnostics and mana...
Drug resistant TB – latest developments in epidemiology, diagnostics and mana...
 
Presentation1-2.pptx
Presentation1-2.pptxPresentation1-2.pptx
Presentation1-2.pptx
 
Dec2010 1final ll
Dec2010 1final llDec2010 1final ll
Dec2010 1final ll
 
The eleven lectures of the Tuberculosis.ppt
The eleven lectures of the Tuberculosis.pptThe eleven lectures of the Tuberculosis.ppt
The eleven lectures of the Tuberculosis.ppt
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Training on tuberculosis for counselors 2012
Training on tuberculosis for counselors 2012Training on tuberculosis for counselors 2012
Training on tuberculosis for counselors 2012
 
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
Tuberculosis and HIV co-infection in the European Union: Epidemiology and tre...
 
Dengue
DengueDengue
Dengue
 
Influence of population density and access to sanitation on covid 19 in mozam...
Influence of population density and access to sanitation on covid 19 in mozam...Influence of population density and access to sanitation on covid 19 in mozam...
Influence of population density and access to sanitation on covid 19 in mozam...
 
Infectious Disease
Infectious DiseaseInfectious Disease
Infectious Disease
 
TOPIC - ABDIKADIR ISSE ABDI (2020-01-01111).pptx
TOPIC - ABDIKADIR ISSE ABDI (2020-01-01111).pptxTOPIC - ABDIKADIR ISSE ABDI (2020-01-01111).pptx
TOPIC - ABDIKADIR ISSE ABDI (2020-01-01111).pptx
 

More from StopTb Italia

PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"StopTb Italia
 
PPT Rizzardini "HAART, sostenibilità di un miracolo"
PPT Rizzardini "HAART, sostenibilità di un miracolo"PPT Rizzardini "HAART, sostenibilità di un miracolo"
PPT Rizzardini "HAART, sostenibilità di un miracolo"
StopTb Italia
 
PPT Ranieri "HIV e TB in carcere"
PPT Ranieri "HIV e TB in carcere"PPT Ranieri "HIV e TB in carcere"
PPT Ranieri "HIV e TB in carcere"StopTb Italia
 
PPT Fiorentini "TB tra ospedale e territorio"
PPT Fiorentini "TB tra ospedale e territorio"PPT Fiorentini "TB tra ospedale e territorio"
PPT Fiorentini "TB tra ospedale e territorio"StopTb Italia
 
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
StopTb Italia
 
PPT Besozzi "Le multiresistenze della TB"
PPT Besozzi "Le multiresistenze della TB"PPT Besozzi "Le multiresistenze della TB"
PPT Besozzi "Le multiresistenze della TB"StopTb Italia
 
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"StopTb Italia
 
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
StopTb Italia
 
PPT Lapadula "Clinica e terapia in TB/HIV"
PPT Lapadula "Clinica e terapia in TB/HIV"PPT Lapadula "Clinica e terapia in TB/HIV"
PPT Lapadula "Clinica e terapia in TB/HIV"StopTb Italia
 
PPT Cirillo "La diagnosi di tubercolosi"
PPT Cirillo "La diagnosi di tubercolosi"PPT Cirillo "La diagnosi di tubercolosi"
PPT Cirillo "La diagnosi di tubercolosi"StopTb Italia
 
PPT Gori "Immunologia TB/HIV"
PPT Gori "Immunologia TB/HIV"PPT Gori "Immunologia TB/HIV"
PPT Gori "Immunologia TB/HIV"
StopTb Italia
 
PPT Bocchino "Diagnosi dell'infezione tubercolare"
PPT Bocchino "Diagnosi dell'infezione tubercolare"PPT Bocchino "Diagnosi dell'infezione tubercolare"
PPT Bocchino "Diagnosi dell'infezione tubercolare"
StopTb Italia
 
PPT Angarano "Storia naturale dell'HIV"
PPT Angarano "Storia naturale dell'HIV"PPT Angarano "Storia naturale dell'HIV"
PPT Angarano "Storia naturale dell'HIV"
StopTb Italia
 
PPT Casali "Storia naturale della TB"
PPT Casali "Storia naturale della TB"PPT Casali "Storia naturale della TB"
PPT Casali "Storia naturale della TB"
StopTb Italia
 
PPT Girardi "Epidemiologia della confezione TB-HIV"
PPT Girardi "Epidemiologia della confezione TB-HIV"PPT Girardi "Epidemiologia della confezione TB-HIV"
PPT Girardi "Epidemiologia della confezione TB-HIV"StopTb Italia
 
PPT Pezzotti "Epidemiologia dell'HIV"
PPT Pezzotti "Epidemiologia dell'HIV"PPT Pezzotti "Epidemiologia dell'HIV"
PPT Pezzotti "Epidemiologia dell'HIV"StopTb Italia
 
PPT Matteelli "Epidemiologia della TB"
PPT Matteelli "Epidemiologia della TB"PPT Matteelli "Epidemiologia della TB"
PPT Matteelli "Epidemiologia della TB"
StopTb Italia
 
PPT Galli "Storia dell'HIV"
PPT Galli "Storia dell'HIV"PPT Galli "Storia dell'HIV"
PPT Galli "Storia dell'HIV"StopTb Italia
 
PPT Perozziello "La Tubercolosi nella medicina e nella cultura: storia e rifl...
PPT Perozziello "La Tubercolosi nella medicina e nella cultura: storia e rifl...PPT Perozziello "La Tubercolosi nella medicina e nella cultura: storia e rifl...
PPT Perozziello "La Tubercolosi nella medicina e nella cultura: storia e rifl...StopTb Italia
 

More from StopTb Italia (20)

PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"PPT Messa "Un tributo pagato dall'arte"
PPT Messa "Un tributo pagato dall'arte"
 
PPT Rizzardini "HAART, sostenibilità di un miracolo"
PPT Rizzardini "HAART, sostenibilità di un miracolo"PPT Rizzardini "HAART, sostenibilità di un miracolo"
PPT Rizzardini "HAART, sostenibilità di un miracolo"
 
PPT Ranieri "HIV e TB in carcere"
PPT Ranieri "HIV e TB in carcere"PPT Ranieri "HIV e TB in carcere"
PPT Ranieri "HIV e TB in carcere"
 
PPT Fiorentini "TB tra ospedale e territorio"
PPT Fiorentini "TB tra ospedale e territorio"PPT Fiorentini "TB tra ospedale e territorio"
PPT Fiorentini "TB tra ospedale e territorio"
 
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
PPT Rusconi "Le multiresistenze dell'HIV/AIDS"
 
PPT Besozzi "Le multiresistenze della TB"
PPT Besozzi "Le multiresistenze della TB"PPT Besozzi "Le multiresistenze della TB"
PPT Besozzi "Le multiresistenze della TB"
 
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
PPT Motta "La farmacologia clinica nella infezione e coinfezione TB/HIV"
 
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
PPT Concia "Localizzazioni extrapolmonari nella coinfezione"
 
PPT Lapadula "Clinica e terapia in TB/HIV"
PPT Lapadula "Clinica e terapia in TB/HIV"PPT Lapadula "Clinica e terapia in TB/HIV"
PPT Lapadula "Clinica e terapia in TB/HIV"
 
PPT Casali
PPT CasaliPPT Casali
PPT Casali
 
PPT Cirillo "La diagnosi di tubercolosi"
PPT Cirillo "La diagnosi di tubercolosi"PPT Cirillo "La diagnosi di tubercolosi"
PPT Cirillo "La diagnosi di tubercolosi"
 
PPT Gori "Immunologia TB/HIV"
PPT Gori "Immunologia TB/HIV"PPT Gori "Immunologia TB/HIV"
PPT Gori "Immunologia TB/HIV"
 
PPT Bocchino "Diagnosi dell'infezione tubercolare"
PPT Bocchino "Diagnosi dell'infezione tubercolare"PPT Bocchino "Diagnosi dell'infezione tubercolare"
PPT Bocchino "Diagnosi dell'infezione tubercolare"
 
PPT Angarano "Storia naturale dell'HIV"
PPT Angarano "Storia naturale dell'HIV"PPT Angarano "Storia naturale dell'HIV"
PPT Angarano "Storia naturale dell'HIV"
 
PPT Casali "Storia naturale della TB"
PPT Casali "Storia naturale della TB"PPT Casali "Storia naturale della TB"
PPT Casali "Storia naturale della TB"
 
PPT Girardi "Epidemiologia della confezione TB-HIV"
PPT Girardi "Epidemiologia della confezione TB-HIV"PPT Girardi "Epidemiologia della confezione TB-HIV"
PPT Girardi "Epidemiologia della confezione TB-HIV"
 
PPT Pezzotti "Epidemiologia dell'HIV"
PPT Pezzotti "Epidemiologia dell'HIV"PPT Pezzotti "Epidemiologia dell'HIV"
PPT Pezzotti "Epidemiologia dell'HIV"
 
PPT Matteelli "Epidemiologia della TB"
PPT Matteelli "Epidemiologia della TB"PPT Matteelli "Epidemiologia della TB"
PPT Matteelli "Epidemiologia della TB"
 
PPT Galli "Storia dell'HIV"
PPT Galli "Storia dell'HIV"PPT Galli "Storia dell'HIV"
PPT Galli "Storia dell'HIV"
 
PPT Perozziello "La Tubercolosi nella medicina e nella cultura: storia e rifl...
PPT Perozziello "La Tubercolosi nella medicina e nella cultura: storia e rifl...PPT Perozziello "La Tubercolosi nella medicina e nella cultura: storia e rifl...
PPT Perozziello "La Tubercolosi nella medicina e nella cultura: storia e rifl...
 

Recently uploaded

Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Dr. Jyothirmai Paindla
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
Gokuldas Hospital
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 

Recently uploaded (20)

Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of HyperthyroidismRole of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 

PPT Codecasa "Urban TB control"

  • 1. La TB nelle aree metropolitane L.R. Codecasa, M. Ferrarese Centro Regionale di Riferimento per il controllo della TBC Istituto Villa Marelli. AO Niguarda, Milano
  • 2. The winter of our discontempt…. (W. Shakespeare, Richard III)
  • 3. TBC nelle grandi città europee 50 Casi  x  100000 45 40 35 30 25 20 15 10 5 0 Londra Milano Rotterdam Barcellona Parigi
  • 4. Trend incidenza TBC e media 2000 - 2010 25 Milano Lombardia Italia Casi  x  100.000 20 19,1 15 10 10,1 5 7,5 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Incidenza nazionale stabile ma con: •  Differenze territoriali rilevanti •  Valori significativamente più elevati nelle aree metropolitane (ASL Milano, notifica il 40% dei casi regionali e il 9% dei casi nazionali di TBC)
  • 5. Numero  casi  TBC  per  fascia  d’età  e  nazionalità  -­‐  2010     Negli  italiani  la  TBC  colpisce  sopra2u2o  gli  anziani,  negli  stranieri  l’età   giovane  –  adulta  con  picco  nella  fascia  30  –  39  anni      
  • 6. TBC  in  stranieri     Area di provenienza 15% Casi TBC dal Sud 27% America - Quota ++ in rapporto ai residenti - - Quota femmine + 25% dei maschi 31% maschi   femmine  
  • 7. RischioTBC  in  stranieri:  10  nazionalità  più  frequen@  a  confronto  con   le  presenze  sul  territorio   * Paesi di origine ad elevata incidenza TBC (≥ 100 casi x
  • 8. "   Il numero dei casi anno è il 5% dei casi totali segnalati "   In media ogni mese viene segnalato 1 caso che frequenta collettività scolastiche "   La proporzione di bambini stranieri è simile a quella dei casi adulti L’andamento della TBC nei bambini non preoccupa, ma esistono nella popolazione i fattori di rischio per lo sviluppo di micro-epidemie nelle comunità infantili
  • 9. POLMONITE  BILATERALE?   " Perù,  13  anni   " Calo  ponderale  15  kg,   febbre,  tosse.   " RichiesO  anOcorpi   anOgliadina!   " QuanOferon  +   " Inviata  per  profilassi   con  isoniazide   " Esame  dire2o  posiOvo   per  BAAR+++  
  • 11. Le Regioni che hanno attivato la sorveglianza ed hanno inviato informazioni sugli esiti sono state Emilia-Romagna, Friuli Venezia Giulia, Lombardia, Marche, Piemonte, Toscana e Veneto, Regioni che rappresentavano il 71% dei casi di TBC notificati a livello nazionale nel 2007 Sono pervenute informazioni sugli esiti di 1.818 casi di TBC polmonare su 2.107. Esiti di trattamento TBC per pervenuti per Regione Anno 2007 D.G. Prevenzione Sanitaria Ufficio Malattie Infettive e Fonte: La tubercolosi in Italia. Rapporto 2008 – www.salute.gov.it Profilassi Internazionale
  • 12. Esi@  della  terapia  casi  di  TBC  2009   Non  pervenuto Sfavorevole Favorevole Cause  esito   sfavorevole   7,4 Perso  al  follow    up   (43%)   19,3   Trasferito  17  %   Decesso  17  %   Interro2o  15%   73,3 Fallimento/altro  8%   Obiettivo OMS: trattare con successo 85% dei casi Differenze significative degli esiti della terapia tra centri ospedalieri: Villa Marelli tratta con successo oltre il 90% dei malati
  • 13.
  • 14.
  • 15. There is an increased drive to use awareness as a measure for TB control and to improve the lack of knowledge, also in EU countries [55]. Mass TB awareness campaigns in general population may not be effective [56], but early suspicion is more likely when knowledge about TB among is increased in the exposed population, high-risk groups, staff working with high-risk groups and health care professionals
  • 16. Infection control in community settings and big cities Infection control (IC) is an essential component of TB control and prevention, including WHO´s updated Stop TB strategy and the EU Standards of TB Care [65-73]. Shortcomings in IC were major contributors to nosocomial outbreaks [74-76], even in European TB reference. Poor ventilation and overcrowding have been drivers of TB transmission in congregate settings such as homeless shelters, prisons and drug consumption houses [78-80]. General IC principles for health care settings, described in detail elsewhere [74, 81], can benefit these specific congregate venues. However, engeneering control activities may be difficult to implement in existing buildings and other measures, such as personal protective equipment for employees, cannot be expected. New interest in IC has been awakened by the emergence of multi-drug resistant (MDR) and extensively-drug resistant (XDR) TB
  • 17. Active case finding among urban high-risk groups should be complemented by tailored opportunities for completion of the diagnostic process and treatment, e.g. through low- threshold public health "One-Stop-TB-Shops" with sufficient nursing, social and community health care worker staff, clinical follow-up or admission to general hospitals or modern-day sanatoria, adequate legal frameworks for social support and protection and ensuring knowledge about and facilitating access to health care services. Contact-tracing may not be feasible or effective amongst all urban risk groups, but can be in specific populations, e.g. household or professional contacts [4, 12]. Indiscriminate radiographic screening of immigrants is described as inefficient and not cost-effective [9, 69, 98, 101, 103]. However, some interventions may be highly effective or cost-effective when targeted at specific urban high-risk groups, e.g. homeless persons and prisoners
  • 18.
  • 19.
  • 20. The contribution of DNA fingerprinting to the epidemiological standard data in the context of urban TB control have been described elsewhere, with an extensive list of references [142]. Briefly, molecular indications for epidemiological links and identification of risk factors for transmission are crucial for understanding the specific epidemiology of TB in big cities, allowing the detection of risk groups and informing (targeted) public health interventions [12, 19]. Since the 1990's DNA fingerprinting revealed that a considerable proportion of TB in low-incidence countries was caused by recent transmission (including reinfection), in particular in urban areas, and not due to late reactivation of infections acquired domestically or infections acquired abroad. Molecular epidemiological studies identified factors for a higher risk of clustering, reflecting the risk of infection, such as alcohol abuse, intravenous drug use (IDU), homelessness, or ethniticy [142]. They also confirmed high-risk sites for TB transmission in big cities, e.g. congregate settings such as shelters for homeless persons or prisons. Not sure this is the best way to phrase this but I was trying to put here what is in the reco : that molecular tools complement the surveillance data
  • 21.
  • 22.
  • 23. Sostenete  Stop  TB  Italia!   www.stoptb.it